2020 Revenues ($USD) : $29,948,845,895
2020 Revenues (foreign currencies) : JP¥3,197,800,000,000
2020 R&D spend : $4,268,773,519
2020 Number of Employees : 47,495
Fiscal Year End : 3/31/2021
Key People : Christophe Weber, representative director, president and CEO; Masato Iwasaki, director, Japan general affairs; Dr. Andrew S. Plump, director, president, R&D; Costa Saroukos, director/CFO; Marcello Agosti, global business development officer; Teresa Bitetti, president, global, oncology business unit; Lauren Duprey, chief human resources officer; Milano Furuta, president, Japan pharma business unit; Gerard Greco, global quality officer; Julie Kim, resident, plasma-derived therapies business unit; Mwana Lugogo, chief ethics and compliance officer; Ricardo Marek, president, growth and emerging markets business unit; Yoshihiro Nakagawa, global general counsel; Takako Ohyabu, chief global corporate affairs officer; Giles Platford, president, Europe and Canada business unit; Koki Sato, corporate strategy officer and chief of staff; Ramona Sequeira, president, U.S. business unit and global portfolio commercialization; Rajeev Venkayya, president, global vaccine business unit; Thomas Wozniewski, global manufacturing and supply officer

The Japanese pharma giant works with health providers and patients in roughly 80 countries. Its research efforts are focused on four therapeutic areas: oncology, rare genetic and hematology, neuroscience, and gastroenterology. Takeda also makes targeted R&D investments in Plasma-Derived Therapies and Vaccines. The company posted in February that it has a pipeline of roughly 40 clinical-stage new molecular entities (NMEs) that is beginning to deliver. They include its TAK-721, which is under priority review at U.S. FDA. TAK-721 remains on track to be the first FDA-approved agent to treat eosinophilic esophagitis. Takeda is also seeking EU regulatory approval for its tetravalent dengue vaccine candidate (TAK-003). –CN